CEO SUMMARY: Healthcare compliance attorneys say the Department of Justice (DOJ) is turning its focus to fraudulent activity related to COVID-19 testing. But that’s not the only area attracting greater scrutiny by the DOJ. Fraud stemming from opioid treatment has snared clinical laboratory companies that ordered medically-unnecessary diagnostic tests. Further, prosecutors have been ordered to […]
Federal Healthcare Fraud Enforcement Turns to Emerging Areas
COVID-19 Testing, Opioid Treatment Come Under DOJ Fire
- By Robert Michel
- > From the Volume XXIX, No. 5 - April 4, 2022 Issue
- Tags: anti kickback statute, Billy Joe Taylor, COVID-19, DOJ, EKRA, false claims act, FBI, FCA, Federal Bureau of Investigation, Fraud, Karen Lovitch, Kevin McGinty, Medicare Part B, Mintz, non-COVID Medicare Part B spending, Opioid treatment, pandemic, Qui Tam, Randy Jones, Redwood Toxicology Laboratory, Samantha Kingsbury, SARS-CoV-2, stark law, telefraud, telehealth fraud, test fraud, U.S. Department of Justice, U.S. District Court for the Western District of Arkansas
